The Goldman Sachs technology M&A team, led by Sam Britton, has cashed in on its software focus and decades of experience to dominate 2019's biggest deals.Technologyread more
American small and medium-size companies that rely on China are scrambling to adjust their business plans in response to the escalating trade war.Traderead more
Here are the products that stand to be the most affected by China's new tariffs on $75 billion worth of U.S. goods.Marketsread more
The summit comes amid fears over a global economic slowdown, and U.S. tensions over trade allies, Iran and Russia.Politicsread more
The world's second biggest economy is past a point where it cannot ignore its enormous debt anymore, according to an analyst.China Economyread more
Carl Medlock used to work at Tesla. Now he's one of the few people in the U.S. that can fix the company's original Roadster electric vehicles.Technologyread more
Trump does have some powerful tools that would not require approval from U.S. Congress.Politicsread more
Stocks dropped after Donald Trump ordered that U.S. manufacturers find alternatives to their operations in China.US Marketsread more
As demand for lab monkeys continues to rise, U.S. scientists are reporting delays in research projects because they can't obtain enough animals, according to the National...Politicsread more
The European Union will respond in kind if the U.S. imposes tariffs on France over digital tax plan, EU chief Donald Tusk told G-7.Technologyread more
Trump said he will raise tariffs on $250 billion in Chinese goods to 30% and hike duties on another $300 billion in products to 15%.Politicsread more
Eli Lilly shares are attractive due to the drug maker's strong pipeline, according to J.P. Morgan.
The firm resumed coverage on Eli Lilly shares with an overweight rating, predicting the company's profit margins will surge over the next few years.
We "see Eli Lilly as fundamentally one of the best positioned names in our group with healthy core product growth (Trulicity, Taltz, Jardiance, etc) and a next wave of late stage pipeline assets," analyst Chris Schott said in a note to clients Wednesday. "Eli Lilly offers combination of top tier growth and high levels of diversification."
Eli Lilly shares rose 0.6 percent Wednesday.
Schott started his Eli Lilly price target at $117, representing 11 percent upside to Tuesday's close.
The analyst noted no drug represents more than 15 percent of the company's sales. He predicts Eli Lilly's operating profit margin will rise to 36 percent by 2024 versus the estimated 27 percent this year.
"We see solid Rx trends for the company's core portfolio of new product launches (Trulicity, Taltz, Jardiance, Basaglar) translating to an ongoing upward bias to estimates," he said.
Eli Lilly shares are up 25 percent this year through Tuesday versus the S&P 500's 9 percent return.